These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36197644)

  • 1. Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World.
    King G; Ittershagen S; He L; Shen Y; Li F; Villacorta R
    Adv Ther; 2022 Dec; 39(12):5433-5452. PubMed ID: 36197644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.
    Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A
    Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
    Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
    Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
    Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
    JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.
    Body A; Wong R; Shapiro J; Jalali A; McLachlan SA; Ananda S; Lipton L; Cooray P; Gibbs P; Lee B; Lee M
    Intern Med J; 2022 Jan; 52(1):49-56. PubMed ID: 33040452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
    Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
    Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
    BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
    Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
    Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
    Pijnappel EN; Dijksterhuis WPM; van der Geest LG; de Vos-Geelen J; de Groot JWB; Homs MYV; Creemers GJ; Mohammad NH; Besselink MG; van Laarhoven HWM; Wilmink JW;
    J Natl Compr Canc Netw; 2021 Aug; 20(5):443-450.e3. PubMed ID: 34450595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence.
    Prejac J; Tomek Hamzić D; Librenjak N; Goršić I; Kekez D; Pleština S
    Medicine (Baltimore); 2022 Sep; 101(39):e30566. PubMed ID: 36181099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe.
    Taieb J; Seufferlein T; Reni M; Palmer DH; Bridgewater JA; Cubillo A; Prager GW; Vermeire A; Hédouin-Biville F; Teng Z; Macarulla T
    BMC Cancer; 2023 Sep; 23(1):877. PubMed ID: 37723453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
    Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
    Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
    Abrams TA; Meyer G; Meyerhardt JA; Wolpin BM; Schrag D; Fuchs CS
    Oncologist; 2017 Aug; 22(8):925-933. PubMed ID: 28476943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
    Doleh Y; Lal LS; Blauer-Petersen C; Antico G; Pishvaian M
    Cancer Med; 2020 May; 9(10):3463-3476. PubMed ID: 32212262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
    Petrillo A; Pappalardo A; Pompella L; Tirino G; Calabrese F; Laterza MM; Caterino M; Ventriglia A; Orditura M; Conzo G; Molino C; Ciardiello F; Biglietto M; De Vita F
    Med Oncol; 2019 Aug; 36(10):83. PubMed ID: 31444639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Pretta A; Ziranu P; Giampieri R; Donisi C; Cimbro E; Spanu D; Lai E; Pecci F; Balconi F; Lupi A; Pozzari M; Persano M; Murgia S; Pusceddu V; Puzzoni M; Berardi R; Scartozzi M
    Dig Liver Dis; 2023 May; 55(5):655-660. PubMed ID: 36513569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of clinical outcomes in metastatic pancreatic adenocarcinoma: a 10-year experience at a tertiary referral center.
    Ellithi M; Abdallah M; Fischer M; Ailts I; Fanta J; Waligoske K; Bell M; Nelson ME; Bleeker J
    Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):479-486. PubMed ID: 35400291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.